Company Insights

VTRS customer relationships

Explore interactive graphBrowse insights index
VTRS customer relationship map

Viatris (VTRS): Customer relationships and what they signal for investors

Viatris is a global, largely generic and specialty pharmaceutical manufacturer that monetizes through three core channels: wholesale distribution to a small set of very large customers, manufacturing and supply contracts with third parties, and select divestitures plus transitional service revenues tied to portfolio streamlining. The company’s revenue base is concentrated among major U.S. and global wholesalers and retail chains, supplemented by contract manufacturing arrangements and temporary transition-service agreements following disposals. For a practical, customer-focused read on counterparties and commercial posture, see https://nullexposure.com/.

How to read Viatris’ customer structure as an investor

Viatris operates at scale and with a consolidated customer concentration profile. The 10‑K lists a short roster of wholesalers and distributors that represent material percentages of consolidated net sales — concrete revenue exposure to a handful of counterparties is an intentional feature of the business, not an anomaly. That structure drives five investment-relevant conclusions:

  • Concentration elevates counterparty risk but supports predictable high-volume flows. A small number of wholesalers deliver scale; losing one would be material to top-line performance.
  • Contracting is mixed: short-term transition services and multi-year manufacturing/supply contracts coexist. The company provides transition services for up to 12 months and enters manufacturing and supply agreements that can run one to ten years, depending on geography and product scope (company-level signal from FY2024 disclosures).
  • Customers are heterogeneous: governments and individual patients are end beneficiaries, while very large enterprises (wholesalers, retailers) are the direct paying customers. The FY2024 filing explicitly identifies governments, payers, wholesalers and retail chains as customer types.
  • Global footprint reduces single-market dependency but increases operational complexity. Viatris reports operations in more than 165 countries and supplying medicines to roughly one billion patients per year, underscoring geographic diversification.
  • Divestitures create a temporary service-provider role and put certain customer relationships into a winding-down phase. Transition services and commercialization support relevant to recent disposals are material to near-term revenue composition.

If you want a structured, counterparty-centric view of Viatris’ customers and how that informs revenue durability, explore more at https://nullexposure.com/.

Customer relationships — line by line

McKesson Corporation

McKesson accounted for roughly 10% of consolidated net sales in 2024 (11% in 2023). Viatris discloses McKesson as a top customer across reporting years, making McKesson one of the most material distribution partners for the company. According to Viatris’ FY2024 10‑K, the table of largest customers lists McKesson at 10% of consolidated sales for 2024.

AmerisourceBergen Corporation / Cencora, Inc.

AmerisourceBergen / Cencora is another top distributor, representing double-digit shares of sales historically (the filings show 12% and 10% figures across years). The FY2024 10‑K lists both AmerisourceBergen and its rebranded form, Cencora, among top customers, confirming continued materiality in the distribution channel.

Cardinal Health, Inc.

Cardinal Health represented approximately 5% of consolidated net sales in the referenced period. Viatris’ FY2024 filing includes Cardinal Health in its customer concentration disclosures, denoting a mid-single-digit revenue share to this major wholesaler.

Pfizer Inc. (manufacturing and supply agreement)

Viatris is party to a Manufacturing and Supply Agreement with Pfizer dating from November 16, 2020, under which Pfizer acts as manufacturer and Viatris as customer. The FY2024 10‑K documents this agreement as a standing contractual relationship, reflecting the company’s reliance on third-party manufacturing arrangements for certain products.

Cooper Consumer Health

Viatris completed the divestiture of its Over‑the‑Counter (OTC) business to Cooper Consumer Health in July 2024, with proceeds and transition implications disclosed. News reporting and the FY2024 10‑K highlight that the sale was part of a broader program of portfolio monetizations that produced over $3.3 billion in proceeds across 2024–2025, and that Viatris provided transition services to support the handoff (news report, FinancialContent, March 2026).

Insud Pharma, S.L.

Insud Pharma acquired Viatris’ women’s healthcare business (primarily oral and injectable contraceptives) in March 2024. The FY2024 filing documents this divestiture and the associated transition arrangements; later reporting reiterates the sale as part of Viatris’ strategic portfolio reductions (news report, March 2026).

Theramex HQ UK Limited

Viatris divested rights to specific women’s healthcare products (Duphaston and Femoston) to Theramex, transferring regional product rights as part of its portfolio simplification. The FY2024 10‑K lists this disposition and associated contractual arrangements for the affected markets.

Matrix Pharma Private Limited

In June 2024 Viatris sold its API business in India to Matrix Pharma Private Limited, completing a disposition of upstream active-pharmaceutical-ingredient operations in that market. The FY2024 filing records the transaction and the handover of the relevant manufacturing assets and customer interfaces.

Viatris Inc. (contract excerpt referencing company roles)

The FY2024 10‑K cites a Manufacturing and Supply Agreement dated November 16, 2020, listing Pfizer as manufacturer and Viatris as customer; this highlights Viatris’ dual role as both a buyer of contract-manufactured product and a seller to wholesale channels. The document-level excerpt clarifies Viatris’ commercial posture in such arrangements.

Constraints and operating-model signals investors should weigh

Viatris’ SEC disclosure provides explicit company-level signals about contracting posture, customer mix, and relationship maturity:

  • Contract tenor is mixed: Transition services are generally limited to up to 12 months, while manufacturing and supply agreements can run one to ten years, subject to extensions (company-level signal from FY2024 disclosures).
  • Counterparty mix spans governments, institutions, individuals and large enterprises, indicating that end-market demand is broad even as payment flows concentrate through a small number of wholesalers.
  • Customer concentration is material: Viatris acknowledges that a significant portion of revenue derives from a limited set of customers; that structural concentration is central to revenue predictability and vendor risk simultaneously.
  • Role diversity: Viatris functions as seller, distributor partner, and temporary service provider (e.g., commercialization and billing services post‑divestiture), and some relationships are explicitly in a winding‑down stage as transition services conclude.

These constraints define the company’s commercial levers: concentrated B2B sales give pricing and volume leverage but create counterparty dependency; staggered contract tenors create predictable near-term cash flows but require active renewal strategy. For customer-level diligence and portfolio implications, visit https://nullexposure.com/.

Investment takeaway and next steps

Viatris’ revenue engine is scale-driven and wholesale-concentrated, supported by contract manufacturing and serial divestitures that reshape earnings composition. The presence of McKesson, AmerisourceBergen/Cencora and Cardinal Health as multi-percent customers makes counterparty dynamics a primary risk vector; conversely, long-term manufacturing agreements and a global footprint underpin operational resilience.

For investors evaluating creditworthiness, revenue durability, or M&A implications, focus on customer retention metrics, renewal cadence for multi-year supply contracts, and timing of transition-service rolloffs. To get a structured view of counterparty exposures and how they affect valuation and risk, explore the NullExposure platform at https://nullexposure.com/.